Senate Hearing On Ozempic, Wegovy Again Highlights Concerns About PBMs

 
• By Cathy Kelly

Senate HELP Committee chair Sanders is trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices for Ozempic and Wegovy. Prominent Republican raises international reference pricing.

Senate HELP Committee screenshot
Novo Nordisk CEO Jorgenson Would Not Commit To Lowering Lists Prices For Ozempic, Wegovy. • Source: Screenshot of Senate HELP Committee broadcast

More from Pricing Debate

More from Market Access